Clarification
Sanofi India Ltd has informed BSE that Company's attention has been invited to reports which have appeared in the newspapers on June 06, 2015 stating that the Competition Commission of India (CCI) has imposed a fine of Rs. 3 crores on Sanofi India for indulging in unfair trade practices. The Company wish to clarify that the CCI has not imposed the fine on Sanofi India Limited, whose shares are listed on Stock Exchanges in India.... Code of Conduct of Fair Disclosure
Sanofi India Ltd has informed BSE about formulation and adoption of Codes under SEBI (Prohibition of Insider Trading) Regulations, 2015. Updates on Results of Postal Ballot
Sanofi India Ltd has submitted to BSE a copy of proceedings of postal ballot through which Ordinary Resolutions were transacted by shareholders of Company on April 10, 2015. Updates on Outcome of AGM
Sanofi India Ltd has submitted to BSE a copy of the Minutes of the 59th Annual General Meeting (AGM) of the Company held on April 29, 2015. Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Sanofi India Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992 Chairmans Speech
Sanofi India Ltd has submitted to BSE a copy of the Speech of the Chairman, Dr. Vijay Mallya delivered at the Annual General Meeting held on April 29, 2015. Shantha Biotech bags Telangana State govt award
Vaccine maker Shantha Biotechnics, an arm of Sanofi Pasteur, has been given the Best Management Award - 2015' by the Government of Telangana. The award was given to the company in recogn... Disclosure of Voting results of AGM (Clause 35A)
Sanofi India Ltd has informed BSE regarding the details of Voting results at the Annual General Meeting (AGM) of the Company held on April 29, 2015, under Clause 35A. Announces Q1 results & Limited Review Report for the Quarter ended March 31, 2015
Sanofi India Ltd has announced the following Unaudited Standalone results for the quarter ended March 31, 2015:The Company has posted a net profit after exceptional items of Rs. 645 million for the quarter ended March 31, 2015 as compared to Rs. 517 million for the quarter ended March 31, 2014. Total Income has increased from Rs. 4664 million for the quarter ended March 31, 2014 to Rs. 5083 million for the quarter ended March 31, 2015. Can Mallya continue on Sanofi India board?
Proxy firm SES says not prudent on part of firm to have him until allegations are cleared. Sanofi India says concerns are premature